| Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes (NCT04997811) | Prof. Janet Dunn | 2021-12-21 |
| Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant (NCT04898790) | University of Nebraska | 2021-11-18 |
| A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes (NCT04985656) | Takeda | 2021-10-01 |
| Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies (NCT06886425) | Assistance Publique Hopitaux De Marseille | 2021-06-14 |
| A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant (NCT04872595) | Memorial Sloan Kettering Cancer Center | 2021-04-30 |
| Pharmacokinetics, Tolerability and Safety of NEX-18a (NCT05048498) | Nanexa AB | 2021-04-27 |
| Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) (NCT04395092) | Kiadis Pharma | 2020-11-13 |
| A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. (NCT04275518) | Ascentage Pharma Group Inc. | 2020-07-06 |
| A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (NCT04202003) | TJ Biopharma Co., Ltd. | 2020-03-25 |
| A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials (NCT04064060) | Celgene | 2019-08-12 |
| TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (NCT03849651) | St. Jude Children's Research Hospital | 2019-01-31 |
| A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS (NCT03593915) | Sumitomo Pharma America, Inc. | 2018-08-29 |
| Panobinostat Maintenance After HSCT fo High-risk AML and MDS (NCT04326764) | Goethe University | 2018-07-24 |
| Collection of Samples From Patients With MDS (NCT03072498) | PersImmune, Inc | 2017-04-06 |
| A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS) (NCT02966782) | AbbVie | 2017-03-07 |
| A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS) (NCT02942290) | AbbVie | 2017-01-12 |
| The National Myelodysplastic Syndromes (MDS) Study (NCT02775383) | National Heart, Lung, and Blood Institute (NHLBI) | 2016-06-13 |
| Red Blood Cell Transfusion Thresholds and QOL in MDS (NCT02099669) | Sunnybrook Health Sciences Centre | 2014-03-01 |
| Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse (NCT01995578) | Memorial Sloan Kettering Cancer Center | 2013-12-01 |
| IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT (NCT01885897) | Masonic Cancer Center, University of Minnesota | 2013-11-11 |
| Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) (NCT01736683) | Merck Sharp & Dohme LLC | 2012-11-28 |
| A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients (NCT01613976) | Novartis Pharmaceuticals | 2012-08-01 |
| Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell (NCT01660607) | Stanford University | 2012-02-09 |
| Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS (NCT01442714) | Stanford University | 2011-08-01 |
| Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders (NCT01392989) | Everett Meyer | 2011-03-01 |
| A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia (NCT01488565) | Peter MacCallum Cancer Centre, Australia | 2010-12-01 |
| Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia (NCT01034592) | Jason Robert Gotlib | 2009-11-01 |
| B-Receptor Signaling in Cardiomyopathy (NCT01135849) | Daniel Bernstein | 2008-11-01 |
| Screening and Genetic Monitoring of Patients With Myelodysplastic Syndromes (MDS) Under Different Treatment Modalities by Cytogenetic Analyses of Circulating CD34+Cells (NCT01355913) | Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH | 2008-10-01 |
| A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes (NCT00600860) | Radboud University Medical Center | 2008-04-01 |
| LBH589 in Refractory Myelodysplastic Syndromes (MDS) (NCT00594230) | SCRI Development Innovations, LLC | 2008-01-01 |
| Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia (NCT00528983) | Celgene | 2007-09-11 |
| A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS) (NCT00230321) | Peter L Greenberg | 2002-02-01 |
| Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders (NCT00186576) | Stanford University | 2001-12-01 |
| Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies (NCT00186342) | Stanford University | 1992-09-01 |